Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 100 movers: AstraZeneca jumps on COPD drug news; Metlen slumps
(Sharecast News) - London's FTSE 100 was flat at 9,976.77 in afternoon trade on Friday. AstraZeneca shot to the top of the index saying its respiratory treatment tozorakimab showed a meaningful reduction in flare-ups of chronic obstructive pulmonary disease (COPD) in two late-stage trials.
3i Group was in the black, recovering from heavy losses in the previous session, after it warned of potential headwinds at portfolio holding Action, a Dutch discount retailer.
Precious metals miner Fresnillo shone, along with miners Rio Tinto, Glencore and Anglo American as gold, silver and copper prices rose.
On the downside, Metlen Energy tumbled as it said full-year results will be delayed by nine days after PricewaterhouseCoopers asked for more time to complete its audit of the first financial statements of the firm as a dual-listed company in the UK and Greece.
Russ Mould, investment director at AJ Bell, said: "The Greek company is enduring a bumpy start to life on the London market, having shifted its listing last summer.
"Guidance was cut in February and delaying results is never a good look."
Housebuilders were under the cosh, with Barratt Redrow and Persimmon both weaker as mortgage rates jumped again.
Defence firms Babcock and Rolls-Royce also lost ground.
FTSE 100 - Risers
AstraZeneca (AZN) 14,256.00p 3.24% 3i Group (III) 2,352.00p 2.70% Rio Tinto (RIO) 6,526.00p 1.73% Fresnillo (FRES) 3,204.00p 1.39% Glencore (GLEN) 538.10p 1.37% NATWEST GROUP (NWG) 540.00p 1.16% Aviva (AV.) 597.00p 1.01% Anglo American (AAL) 3,068.00p 0.92% Croda International (CRDA) 2,857.00p 0.88% Tesco (TSCO) 458.00p 0.77%
FTSE 100 - Fallers
Metlen Energy & Metals (MTLN) 32.45p -6.62% Babcock International Group (BAB) 1,165.00p -3.63% Barratt Redrow (BTRW) 258.80p -3.43% Pershing Square Holdings Ltd NPV (PSH) 3,830.00p -3.13% Persimmon (PSN) 1,085.00p -2.95% British Land Company (BLND) 344.60p -2.93% Rolls-Royce Holdings (RR.) 1,112.50p -2.78% Entain (ENT) 538.80p -2.49% Informa (INF) 746.40p -2.38% Smurfit Westrock (DI) (SWR) 2,954.00p -2.32%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
